fmcg otc healthcare

Here's some not to be relied upon speculation....

I reckon that for reasons already discussed on OBJ threads but principally this comment from the April 2011 update

"...has now moved to being reviewed by FMCG's international marketing department"

the FMCG OTC Healthcare will be the first partner to announce a commercialisation agreement.

I also reckon that FMCG OTC Healthcare is Novartis (as one of the Usual Suspects has already speculated historically). The first product that OBJ technology will be used in will be the NSAID Voltaren Emulgel, which OBJ DP technology has shown a 100% increase in ex vivo trials.

With the current concerns around drugs like Voltaren and Nurofen increasing the risk of stroke ...
(http://www.smh.com.au/lifestyle/diet-and-fitness/study-links-voltaren-and-nurofen-to-strokes-20100913-159d6.html)

... Novartis will argue that their topically applied Emulgel (with enhanced magnetophoresis) means that we the consumer can get the same targeted effect with less of the drug having to be in the body compared to gastro-intestinal application.

Also this from the April update ...

"In addition, interest from another product group within the same FMCG Company has created further potential product development opportunities for the Company."

Despite a very large OTC division, Novartis also have large pharmaceutical, animal health, generics and vaccines divisions which would all have product groups that may have application to OBJ technology. Their stop-smoking product Nicotinell could be another likely candidate.

When will it happen – no idea - but Monday would be nice.

bluebush